NeuroSigma wins FDA nod for first non-drug ADHD treatment
The company's cell phone-sized device delivers low-level electric stimulation to the trigeminal nerve through a patch placed on a patient's forehead.
Epilepsy device developer NeuroSigma has withdrawn its $50M IPO plans
The Los Angeles-based company developing its drug-resistant epilepsy system has officially backed out of its IPO plans.
presented by
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.